COVID UPDATE 11/23 2:41PM PST

There's more good news about potential vaccines to prevent SARS-CoV-2. And this time, the news comes from pharmaceutical company, "Astrazenca."

An excerpt from a public article in STAT news explains the following:

"AstraZeneca said Monday that its coronavirus vaccine reduced the risk of symptomatic Covid-19 by an average of 70.4%, according to an interim analysis of large Phase 3 trials conducted in the United Kingdom and Brazil.

The results, while positive, suggest the vaccine may be less effective than two others. Earlier this month, Moderna and the Pfizer and BioNTech consortium announced their messenger RNA, or mRNA, vaccines showed 95% efficacy against Covid-19 infections in their respective clinical trials.

Still, researchers at the University of Oxford, which partnered with AstraZeneca to develop the vaccine, hailed the latest data as promising."

Click here to read the full article on STAT News.

---